5 min read
How a Vaccine Gets Made: From Lab to Injection
A single vaccine can take a decade to reach a pharmacy shelf. Here's every stage it passes through, and why each one exists.
Infographic or illustration goes here. Drop one into /public and swap this placeholder for a next/image.
It's easy to see a vaccine appear in the news and assume it came together overnight. In reality, almost every vaccine passes through the same sequence of stages, each one designed to catch a different kind of problem before it ever reaches a patient.
Discovery & design
Researchers identify a viral or bacterial target and design a candidate vaccine to trigger an immune response against it.
Preclinical testing
The candidate is tested in cell cultures and animal models to check basic safety and whether it triggers the intended immune response at all.
Phase I trials
A small group of healthy volunteers (tens of people) receives the vaccine to check for safety and rough dosing.
Phase II trials
A larger group (hundreds of people) helps narrow down the right dose and confirms the immune response is consistent.
Phase III trials
Thousands of participants across multiple sites test whether the vaccine actually prevents disease in the real world, and surface rarer side effects.
Regulatory review
Agencies like the FDA independently review all trial data before granting approval or authorization.
Manufacturing & distribution
Approved vaccines are produced at scale under strict quality controls, then distributed through cold chains built to keep them effective.
Post-market monitoring
Safety monitoring continues indefinitely after approval, tracking rare side effects that only show up across millions of doses.
Why mRNA vaccines moved faster
Traditional vaccines can take 10-15 years to reach approval. mRNA platforms compress that timeline because the manufacturing process is largely identical regardless of the target, only the genetic sequence changes, so companies could begin scaling production before Phase III trials even finished.
None of the stages above were skipped for COVID-19 vaccines. What changed was the amount of parallel investment, and years of prior mRNA research that was already sitting on the shelf.